Jason W Denbo1, Suguru Yamashita1, Guillaume Passot1, Michael Egger1, Yun S Chun1, Scott E Kopetz2, Dipen Maru3, Kristoffer Watten Brudvik1, Steven H Wei1, Claudius Conrad1, Jean-Nicolas Vauthey1, Thomas A Aloia4. 1. Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1484, Houston, TX, 77030, USA. 2. Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 3. Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 4. Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1484, Houston, TX, 77030, USA. taaloia@mdanderson.org.
Abstract
BACKGROUND: The relationship between RAS mutation status and outcome for patients undergoing repeat hepatectomy (RH) for recurrent colorectal liver metastases (CLM) has not been defined. OBJECTIVE: The objective of this study was to evaluate the relationship between RAS mutation status and outcome in patients undergoing RH for CLM. METHODS: All patients who underwent RH for CLM with known RAS mutation status between January 2005 and November 2014 were identified, and the outcomes of patients with and without RAS mutations were compared. RESULTS: Ninety-eight patients underwent RH, of whom 34 (35 %) harbored a RAS mutation. Wild-type (WT) and mutant RAS groups had similar clinicopathologic characteristics. Median recurrence-free survival (RFS) for patients with WT and mutant RAS was 12.2 and 6.1 months, respectively (p = 0.03). Median overall survival (OS) for the WT and mutant RAS patients were 42.5 and 26.6 months, respectively (p < 0.01). On multivariate analysis, RAS mutations [hazard ratio (HR) = 1.69, p = 0.04] were associated with worse RFS, while multiple tumors (HR = 1.92, p = 0.045) and RAS mutations (HR = 2.11, p = 0.02) predicted worse OS. CONCLUSION: Patients with recurrent CLM that harbor RAS mutations have worse RFS and OS than patients with WT RAS, and RAS mutations are independently associated with worse RFS and OS. RAS mutation status should be determined prior to RH, as it may impact treatment decisions.
BACKGROUND: The relationship between RAS mutation status and outcome for patients undergoing repeat hepatectomy (RH) for recurrent colorectal liver metastases (CLM) has not been defined. OBJECTIVE: The objective of this study was to evaluate the relationship between RAS mutation status and outcome in patients undergoing RH for CLM. METHODS: All patients who underwent RH for CLM with known RAS mutation status between January 2005 and November 2014 were identified, and the outcomes of patients with and without RAS mutations were compared. RESULTS: Ninety-eight patients underwent RH, of whom 34 (35 %) harbored a RAS mutation. Wild-type (WT) and mutant RAS groups had similar clinicopathologic characteristics. Median recurrence-free survival (RFS) for patients with WT and mutant RAS was 12.2 and 6.1 months, respectively (p = 0.03). Median overall survival (OS) for the WT and mutant RAS patients were 42.5 and 26.6 months, respectively (p < 0.01). On multivariate analysis, RAS mutations [hazard ratio (HR) = 1.69, p = 0.04] were associated with worse RFS, while multiple tumors (HR = 1.92, p = 0.045) and RAS mutations (HR = 2.11, p = 0.02) predicted worse OS. CONCLUSION:Patients with recurrent CLM that harbor RAS mutations have worse RFS and OS than patients with WT RAS, and RAS mutations are independently associated with worse RFS and OS. RAS mutation status should be determined prior to RH, as it may impact treatment decisions.
Authors: Jean-Nicolas Vauthey; Giuseppe Zimmitti; Scott E Kopetz; Junichi Shindoh; Su S Chen; Andreas Andreou; Steven A Curley; Thomas A Aloia; Dipen M Maru Journal: Ann Surg Date: 2013-10 Impact factor: 12.969
Authors: Henrik Petrowsky; Mithat Gonen; William Jarnagin; Matthias Lorenz; Ronald DeMatteo; Stefan Heinrich; Albrecht Encke; Leslie Blumgart; Yuman Fong Journal: Ann Surg Date: 2002-06 Impact factor: 12.969
Authors: Timothy M Pawlik; Charles R Scoggins; Daria Zorzi; Eddie K Abdalla; Axel Andres; Cathy Eng; Steven A Curley; Evelyne M Loyer; Andrea Muratore; Gilles Mentha; Lorenzo Capussotti; Jean-Nicolas Vauthey Journal: Ann Surg Date: 2005-05 Impact factor: 12.969
Authors: Georgios Karagkounis; Michael S Torbenson; Hubert D Daniel; Nilofer S Azad; Luis A Diaz; Ross C Donehower; Kenzo Hirose; Nita Ahuja; Timothy M Pawlik; Michael A Choti Journal: Cancer Date: 2013-09-19 Impact factor: 6.860
Authors: Dan G Blazer; Yoji Kishi; Dipen M Maru; Scott Kopetz; Yun Shin Chun; Michael J Overman; David Fogelman; Cathy Eng; David Z Chang; Huamin Wang; Daria Zorzi; Dario Ribero; Lee M Ellis; Katrina Y Glover; Robert A Wolff; Steven A Curley; Eddie K Abdalla; Jean-Nicolas Vauthey Journal: J Clin Oncol Date: 2008-10-20 Impact factor: 44.544
Authors: M Schirripa; F Bergamo; C Cremolini; M Casagrande; S Lonardi; G Aprile; D Yang; F Marmorino; G Pasquini; E Sensi; C Lupi; G De Maglio; N Borrelli; S Pizzolitto; G Fasola; R Bertorelle; M Rugge; G Fontanini; V Zagonel; F Loupakis; A Falcone Journal: Br J Cancer Date: 2015-05-05 Impact factor: 7.640
Authors: M Okuno; C Goumard; T Mizuno; S Kopetz; K Omichi; C-W D Tzeng; Y S Chun; J E Lee; J-N Vauthey; C Conrad Journal: Br J Surg Date: 2018-04-17 Impact factor: 6.939
Authors: Raja R Narayan; Jashodeep Datta; Debra A Goldman; Victoria G Aveson; Henry S Walch; Francisco Sanchez-Vega; Mithat Gönen; Vinod P Balachandran; Jeffrey A Drebin; William R Jarnagin; T Peter Kingham; Alice C Wei; Nikolaus Schultz; Nancy E Kemeny; Michael I D'Angelica Journal: Ann Surg Oncol Date: 2022-07-27 Impact factor: 4.339
Authors: Bruno C Odisio; Suguru Yamashita; Steven Y Huang; Scott E Kopetz; Kamran Ahrar; Takashi Mizuno; Claudius Conrad; Thomas A Aloia; Yun Shin Chun; Sanjay Gupta; Jean-Nicolas Vauthey Journal: J Vasc Interv Radiol Date: 2018-02-01 Impact factor: 3.464
Authors: Suguru Yamashita; Aradhana M Venkatesan; Takashi Mizuno; Thomas A Aloia; Yun S Chun; Jeffrey E Lee; Jean-Nicolas Vauthey; Claudius Conrad Journal: JAMA Surg Date: 2017-10-18 Impact factor: 14.766